CBAN
Colony Bankcorp, Inc.
CBAN's fundamentals are strong: revenue grew 28% and its operating margin rose 2 points to 29%. At 11x earnings, it's trading right at its usual valuation. Analysts expect earnings growth.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CBAN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CBAN's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CBAN.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CBAN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $20.30 | — |
| Cheap | 9.4x | $17.14 | -16% |
| Fair | 11x | $20.26 | -0.2% |
| Current | 11x | $20.30 | — |
| Expensive | 13x | $22.83 | +12% |
Historical ranges are pointers, not guarantees.
CBAN's PE is in its fair range at 11x. If earnings grow as analysts expect, today's price would be 8.9x next year's earnings, in its cheap range.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CBAN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CBAN, but weaker profitability.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CBAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.28 | +25% |
| Q3 2026 | $1.82 | +14% |
| Q2 2026 | $1.65 | +3.8% |
| Q1 2026 | $1.60 | +11% |
| Q4 2025 | $1.59 | +17% |
| Q3 2025 | $1.60 | +28% |
| Q2 2025 | $1.59 | +26% |
| Q1 2025 | $1.44 | +15% |
| Q4 2024 | $1.36 | +9.7% |
CBAN has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CBAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.6M | +30% |
| Q2 2026 | $42M | +29% |
| Q1 2026 | $39.9M | +33% |
| Q4 2025 | $36.9M | +20% |
| Q3 2025 | $32.8M | +15% |
| Q2 2025 | $32.5M | +16% |
| Q1 2025 | $30M | +6.6% |
| Q4 2024 | $30.8M | +9.2% |
CBAN's revenue has grown year over year for eight quarters in a row: $43M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +9.1 points |
| Q2 2026 | 33% | +1.7 points |
| Q1 2026 | 26% | -1.3 points |
| Q4 2025 | 26% | -2.9 points |
| Q3 2025 | 22% | -2.4 points |
| Q2 2025 | 31% | +6.1 points |
| Q1 2025 | 28% | +3.6 points |
| Q4 2024 | 29% | +3.6 points |
CBAN has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CBAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | -67% |
| Q2 2026 | $8.2M | -48% |
| Q1 2026 | $53.8M | +206% |
| Q4 2025 | -$54.3M | -$50.5M |
| Q3 2025 | $14.1M | -30% |
| Q2 2025 | $15.8M | +1492% |
| Q1 2025 | $17.6M | +257% |
| Q4 2024 | -$3.8M | -174% |
CBAN has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CBAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +60.6K shares |
| 1 year | +22% | +3.8M shares |
| 3 years | +21% | +3.7M shares |
| 5 years | +123% | +11.7M shares |
| Available history | +132% | +12.1M shares |
CBAN has 21M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $1.8M |
| Q4 2025 | $779,000 |
| Q3 2025 | — |
| Q2 2025 | $959,000 |
| Q1 2025 | $630,000 |
| Q4 2024 | $540,000 |
CBAN spent $3M buying back its own shares over the past year, up 20% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has the edge over CBAN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CBAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 7.4x | High |
| Q1 2026 | 9.2x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 9.7x | High |
| Q2 2025 | 9.7x | High |
| Q1 2025 | 11.1x | High |
| Q4 2024 | 5.9x | High |
CBAN's net debt is about 8.5 years of its operating earnings (EBITDA), down from 9.7 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CBAN.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CBAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.0 | Neutral |
| Stochastic | 25.3 | Neutral |
CBAN's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CBAN PE vs Financial Services Sector
| Metric | CBAN | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 14% below |
| PE % | 50 | 63 | 13 pts below |
CBAN is trading at 11x earnings, a 14% discount to the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CBAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.3 | 0.2% above |
| 20 week MA | $20.9 | 2.9% below |
| 50 week MA | $20.1 | 0.9% above |
| 100 week MA | $18.2 | 12% above |
| 200 week MA | $15.1 | 34% above |
CBAN has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CBAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.5 | $14.1 | -14% |
| 2021 | $14.1 | $16.8 | +19% |
| 2022 | $16.8 | $12.9 | -23% |
| 2023 | $12.9 | $13.3 | +3.1% |
| 2024 | $13.3 | $16.3 | +22% |
| 2025 | $16.3 | $18.1 | +11% |
| 2026 YTD | $18.1 | $20.3 | +12% |
CBAN has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.